Latest Breaking News On - Georg goliasch - Page 1 : comparemela.com
Research Finds Prevalence and Outcomes of Cardiac Amyloidosis via Nuclear Med Bone Scan
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Secondary Mitral Regurgitation Common, Undertreated in HF
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Study: Valvular heart disease in patients with chronic heart failure has been underestimated
Hitherto, the development of valvular heart disease in patients with chronic heart failure has been underestimated and rarely treated. This is the finding of a study conducted at the Division of Cardiology within the Department of Medicine II at Vienna General Hospital and MedUni Vienna and published in the prestigious
British Medical Journal (BMJ). Mitral regurgitation was often previously interpreted as part of the progression of heart failure rather than a treatable disease in its own right.
Mitral regurgitation is a disease, in which the valve between the left atrium and left ventricle starts to leak, so that blood refluxes with each heartbeat. Typical symptoms of mitral regurgitation are increasing fatigue, increased shortness of breath on physical exertion and water retention in the lungs and legs. Mitral regurgitation is frequently also associated with cardiac arrhythmias such as a
Valvular heart disease: The underestimated risk of a common disease
eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
May 19, 2021
Preliminary 2-year results from the single-arm CLASP study show that mitral valve repair using the Pascal transcatheter system is associated with high rates of survival and freedom from rehospitalization as well as a durable reduction in mitral regurgitation (MR).
According to Molly Szerlip, MD (Baylor Scott & White Health, Plano, TX), who virtually presented the study as a late breaker at EuroPCR 2021, the data look “extremely good,” at least for the numbers of patients followed so far, in both functional and degenerative MR.
“This reiterates that this is an excellent device and one that needs to be out on the market,” she told TCTMD. “And as the long-term data come out, there s nothing that would make us think that [this device] is not going to continue to have excellent long-term outcomes.”